Cat. No. 3823
Chemical Name: 4-[5-[8-(1-Methylethyl)-4-phenyl-2-
Biological ActivityAntagonist of RARα receptors (IC50 = 31.2 nM). Displays selective affinity for RARα (relative IC50 values are 1.8, 432 and 535 nM for RARα, RARγ and RARβ respectively).
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Datasheet
References are publications that support the products' biological activity.
Somenzi et al (2007) Disruption of retinoic acid receptor alpha reveals the growth promoter face of retinoic acid. PLoS ONE 9 e836. PMID: 17786207.
Ren et al (2005) Impaired retinoic acid (RA) signal leads to RARβ2 epigenetic silencing and RA resistance. Mol.Cell.Biol. 25 10591. PMID: 16287870.
Kikuchi et al (2001) Syntheses and evaluation of quinoline derivatives as novel retinoic acid receptor α antagonists. Bioorg.Med.Chem.Lett. 11 1215. PMID: 11354380.
If you know of a relevant reference for ER 50891 please let us know.
Citations are publications that use Tocris products. Selected citations for ER 50891 include:
Centritto et al (2015) Cellular and molecular determinants of all-trans retinoic acid sensitivity in breast cancer: Luminal phenotype and RARα expression. J Reprod Dev 7 950. PMID: 25888236.
Do you know of a great paper that uses ER 50891 from Tocris? If so please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: ER 50891, supplier, ER50891, raralpha, rara, rarα, receptors, antagonists, retinoids, retinoic, acid, selective, Tocris Bioscience, Retinoic Acid Receptor Antagonist products
Find multiple products by catalog number
New Products in this Area
Synthetic progesterone analogC-DIM 12
Nurr1 activator; inhibits NF-κB-dependent gene expression(S)-Equol
Potent estrogen receptor β (ERβ) agonistAilanthone
Potent inhibitor of androgen receptor (AR)(±)-ML 209
RORγt inverse agonist; suppresses Th17 cell differentiationAGN 193109
High affinity pan-RAR antagonistSR 9243
Selective LXR inverse agonist
June 14 - 17, 2017
Boston, MA, USA